Ellie Kincaid is an editor at Retraction Watch. Her work has appeared in STAT, The Wall Street Journal, Forbes, WebMD and Medscape. She has a B.A. in English from Washington University in St. Louis and an M.A. in journalism from New York University’s Science, Health and Environmental Reporting Program.
Ellie Kincaid
Editor
Retraction Watch
From this contributor
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
By
Brendan Borrell, Ellie Kincaid
8 October 2024 | 3 min read
Head of company that accredits autism service providers resigns after article retraction
The resignation follows reporting by Spectrum and Retraction Watch in October about nonexistent references in the retracted article.
Head of company that accredits autism service providers resigns after article retraction
By
Ellie Kincaid
29 November 2023 | 4 min read
Article defending private-equity involvement in autism services retracted
Nearly two-thirds of the article’s references appear to not exist.
Article defending private-equity involvement in autism services retracted
By
Ellie Kincaid, Retraction Watch
19 October 2023 | 5 min read
Explore more from The Transmitter
Frameshift: Shari Wiseman reflects on her pivot from science to publishing
As chief editor of Nature Neuroscience, Wiseman applies critical-thinking skills she learned in the lab to manage the journal’s day-to-day operations.
Frameshift: Shari Wiseman reflects on her pivot from science to publishing
As chief editor of Nature Neuroscience, Wiseman applies critical-thinking skills she learned in the lab to manage the journal’s day-to-day operations.
By
Katie Moisse
15 December 2025 | 7 min read
How basic neuroscience has paved the path to new drugs
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research.
How basic neuroscience has paved the path to new drugs
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research.
By
Alex Kwan
15 December 2025 | 6 min read
Dispute erupts over universal cortical brain-wave claim
The debate highlights opposing views on how the cortex transmits information.
Dispute erupts over universal cortical brain-wave claim
The debate highlights opposing views on how the cortex transmits information.
By
Claudia López Lloreda
12 December 2025 | 5 min read